Medical Affairs has traditionally been an under-represented function in pharmaceutical decision-making. Yet more recently leading pharmaceutical companies have started to make much better use of Medical Affairs’ ability to understand and amplify the patient voice, resulting in higher quality R&D and Commercial decision-making.
In this webinar, Andrew Bell of Novasecta was joined by Jill Massey (Vice President, Global Medical Strategic Operations at Gilead Sciences), Anders Neijber (Vice president, Global Medical Affairs and Clinical Development at Photocure), and Taru Blom (Vice President and Chief Medical Officer, R&D Global Development and Medical Affairs at Orion Corporation) to discuss their thoughts on how Medical Affairs creates value in pharmaceutical companies, and to share their insights on how reimagining the role can deliver superior value to both patients and organisations.
In this discussion, our panel share their experiences and perspectives on a range of topics, including:
- How to make sure Medical Affairs has a voice in pharmaceutical decision-making, and the benefits of doing so.
- The importance of strong collaboration between Medical Affairs, R&D and Commercial functions, and how this is best achieved.
- Industry examples of how a strong Medical Affairs capability can be transformative for pharmaceutical companies.
If you are a Medical Affairs, Commercial or R&D leader who can see the value of reimagining Medical Affairs in your organisation, this will be an incredibly valuable session.
Click here to watch now.